The results demonstrated that high PIEZO1 expression remained an independent risk factor for poor prognosis across multiple cancers, significantly shortening OS, DSS, and PFI in patients with various cancer types (HR > 1, p < 0.05); (Supplementary Figures 5B–D). This evidence concerns the gene PIEZO1 and cancer.